Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800) : A trial of the eastern cooperative oncology group

✍ Scribed by Robert Dreicer; Shuli Li; Judith Manola; Naomi B. Haas; Bruce J. Roth; George Wilding

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 89 KB
• Volume: 110
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.22839

✦ Synopsis

Abstract

BACKGROUND.

Paclitaxel and docetaxel are active agents in advanced urothelial cancer. BMS‐247550 (ixabepilone) has activity in preclinical models in paclitaxel resistant models. A phase 2 trial of this epothilone was performed to determine the activity and toxicity of this agent in a multi‐institutional setting in patients previously treated with 1 prior chemotherapy regimen.

METHODS.

Forty‐five patients with advanced urothelial carcinoma were treated with BMS‐247550 40 mg/m^2^ over 3 hours intravenously on Day 1 of a 21‐day cycle and continued therapy until progression or unacceptable toxicity.

RESULTS.

Five patients obtained an objective partial response (PR) among the 42 eligible patients for an overall response rate of 11.9% (90% confidence interval [5.3%, 26.5%]). Median overall survival of the group was 8 months. Toxicity was moderate with granulocytopenia, fatigue, and sensory neuropathy being the most common side effects noted.

CONCLUSIONS.

BMS‐247550 (ixabepilone) has very modest activity as a second‐line therapy for advanced urothelial cancer. Responses in visceral, nodal, and soft tissues sites were observed. Granulocytopenia without fever, fatigue, and sensory neuropathy was common. Cancer 2007. © 2007 American Cancer Society.